Respiratory Disease Vaccine Market Report 2026

The respiratory disease vaccine market size has grown marginally in recent years. It will grow from $70.03 billion in 2025 to $71.36 billion in 2026 at a compound annual growth rate (CAGR) of 1.9%. The growth in the historic period can be attributed to high prevalence of respiratory infections, limited availability of effective vaccines, government immunization initiatives, advancements in monoclonal antibody research, rising awareness about respiratory health.

The respiratory disease vaccine market size is expected to see steady growth in the next few years. It will grow to $81 billion in 2030 at a compound annual growth rate (CAGR) of 3.2%. The growth in the forecast period can be attributed to increasing demand for universal vaccines, technological advances in mRNA and viral vector vaccines, expansion of cold-chain infrastructure, growth in public-private partnerships for vaccine distribution, focus on pandemic preparedness and rapid response. Major trends in the forecast period include development of next-generation respiratory vaccines, increased focus on pediatric and geriatric immunization, expansion of immunization programs in emerging markets, rise of combination vaccines for multi-pathogen protection, adoption of rapid vaccine development and distribution platforms.

The increasing incidence of tuberculosis (TB) is expected to drive the growth of the respiratory disease vaccine market in the coming years. Tuberculosis is an infectious respiratory disease caused by Mycobacterium tuberculosis, mainly affecting the lungs and posing a major global health challenge. The rise in TB cases is influenced by factors such as weakened healthcare systems, delays in diagnosis, and wider transmission patterns, all contributing to a higher disease burden. Respiratory disease vaccines are essential in reducing TB-related risks by lowering infection rates, curbing transmission, and supporting global prevention efforts. For example, in March 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, an increase of 1,295 cases. Thus, the growing incidence of tuberculosis is fueling the expansion of the respiratory disease vaccine market.

Major companies in the respiratory disease vaccine market are focusing on developing innovative products to improve their effectiveness and offer better solutions for preventing and managing respiratory disease infections. For example, in May 2023, Pfizer Inc., a US-based pharmaceutical company, obtained Food and Drug Administration (FDA) approval for ABRYSVO (Respiratory Syncytial Virus Vaccine), the bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals aged 60 years and older. ABRYSVO is an unadjuvanted vaccine composed of two preF proteins designed to enhance immunity against RSV A and B strains and has been clinically demonstrated to be safe and effective.

In February 2024, AstraZeneca Plc, a UK-based biopharmaceutical company, acquired Icosavax, Inc. for an undisclosed amount. Through this acquisition, AstraZeneca aims to strengthen its vaccine development capabilities and broaden its pipeline of next-generation immunotherapies. Icosavax, Inc. is a US-based biotechnology company focused on developing virus-like particle (VLP) vaccines targeting infectious diseases.

Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc, CureVac N.V., Incepta Vaccine Ltd, Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.

Asia-Pacific was the largest region in the respiratory disease vaccine market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the respiratory disease vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the respiratory disease vaccine market by increasing the cost of raw materials, biopharmaceutical reagents, and manufacturing equipment, leading to higher production costs for vaccine manufacturers. This impact is particularly significant in segments like viral and bacterial vaccines and regions such as North America, Europe, and Asia-Pacific, where a large portion of vaccine components are imported. While tariffs pose challenges, they have also encouraged local production initiatives, boosting domestic manufacturing capabilities and supply chain resilience.

The respiratory disease vaccine market research report is one of a series of new reports that provides respiratory disease vaccine market statistics, including respiratory disease vaccine industry global market size, regional shares, competitors with a respiratory disease vaccine market share, detailed respiratory disease vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory disease vaccine industry. This respiratory disease vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Respiratory diseases encompass a variety of conditions that impact the lungs and airways, resulting in breathing difficulties and respiratory symptoms. A respiratory disease vaccine is a type of immunization aimed at protecting individuals from infections caused by viruses or bacteria that mainly target the respiratory system, including the lungs and airways. These vaccines function by triggering the immune system to generate antibodies that can identify and combat the specific pathogen responsible for the disease.

The main types of respiratory disease vaccines include viral vaccines, bacterial vaccines, and combination vaccines. A viral vaccine is a preparation containing weakened or inactivated viruses that trigger immune responses and are used to prevent respiratory diseases by preparing the immune system to recognize and combat specific viruses, thereby reducing infection spread and severity. They are applied in preventing infections such as COVID-19, influenza, respiratory syncytial virus (RSV), pneumonia, and others in infants, adolescents, and adults in clinics, hospitals, and other healthcare settings.

The respiratory diseases vaccine market consists of sales of the rotavirus vaccine, bordetella vaccine and varicella (chickenpox) vaccine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.